United States · Platforms & data · The Motley Fool

CME vs. Nu: Which Financial Stock Is a Better Buy for 2027?

Published by The Motley Fool · United States 57 min ago

CME boasts a 62% net margin and fortress balance sheet, while Nu's 43% revenue growth signals emerging-market momentum, but their risk profiles diverge sharply.

Read the full article on The Motley Fool Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

CNBC

Treasury yields fall after Democrats win House and Senate majorities

MarketWatch

CVS Health plans to split in two. Here’s what is driving the massive healthcare breakup.

Benzinga

CME vs. Nu: Which Financial Stock Is a Better Buy for 2027?

Share

Also worth reading

Treasury yields fall after Democrats win House and Senate majorities

CVS Health plans to split in two. Here’s what is driving the massive healthcare breakup.

Best Stocks Under $5

CS Disco LLC earnings missed by $0.06, revenue topped estimates

Market News

HC Wainwright & Co. upgrades Inovio Pharmaceuticals to Buy from Neutral, sets price target at $5